Related Experiment Video
Updated: Aug 14, 2026

Echocardiographic Approaches and Protocols for Comprehensive Phenotypic Characterization of Valvular Heart Disease in Mice
Published on: February 14, 2017
[Serial clinical and echocardiographic evaluation in children with Marfan syndrome]
Victor Manuel Oporto Lopez1, Ana Beatriz Alvarez Perez, Valdir Ambrósio Moisés
1Universidade Federal de São Paulo, São Paulo, SP. victoroporto666@hotmail.com
Insights
Pediatric Marfan syndrome (MFS) patients showed high rates of annuloaortic ectasia and mitral valve prolapse. Beta-blockers effectively lowered heart rate in children with MFS, with no significant adverse effects observed.
Area of Science:
- Cardiology
- Pediatric Cardiology
- Genetics
Background:
- Marfan syndrome (MFS) is a genetic disorder affecting connective tissue.
- Cardiac manifestations, including aortic root dilation and mitral valve prolapse, are common in MFS.
- Understanding the temporal evolution of cardiac issues and treatment efficacy in pediatric MFS is crucial.
Purpose of the Study:
- To detail cardiac manifestations and their progression in pediatric Marfan syndrome.
- To determine the incidence of annuloaortic ectasia and mitral valve prolapse.
- To assess the safety and effectiveness of beta-blocker therapy in these children.
Main Methods:
- Serial clinical and echocardiographic evaluations over one year in 21 pediatric MFS patients.
- Assessment of mitral valve prolapse, aortic root diameter, and valve regurgitation.
- Monitoring aortic root diameter changes during beta-blocker treatment.
Main Results:
- Annuloaortic ectasia occurred in 76% of patients, exceeding mitral valve prolapse (52%).
- Beta-blockers significantly reduced heart rate (13.6%) but aortic root diameter increased (1.4 mm/year).
- One patient required aortic valve replacement; beta-blockers were well-tolerated, with one contraindication due to asthma.
Conclusions:
- Pediatric MFS patients can remain asymptomatic with beta-blocker therapy, which lowers heart rate without significant side effects.
- The high incidence of annuloaortic ectasia in this cohort contrasts with existing literature.
- Beta-blocker therapy warrants continued investigation for managing cardiac complications in pediatric Marfan syndrome.
Objective:
To describe the clinical cardiac manifestations and temporal evolution of Marfan syndrome in children; to estimate the incidence of annuloaortic ectasia and mitral valve prolapse; and to evaluate tolerability and efficacy of beta-blockers in these patients.
Methods:
During one year, 21 children with Marfan syndrome underwent serial clinical and echocardiographic examinations. Echocardiograms assessed: the presence of mitral valve prolapse, aortic root diameter, mitral and aortic valves regurgitation, and aortic enlargement during beta-blocker therapy. Eleven patients had two measurements of the aortic root taken one year apart.
Results:
The children were asymptomatic throughout the study. Mitral prolapse was found in 11 (52%) children. Annuloaortic ectasia occurred in 16 (76%) patients and found to be mild in 42.8%, moderate in 9.5%, and severe in 23.8%. One of these patients underwent aortic valve replacement and repair of the ascending aorta by the Bentall-De Bono technique, with good results. Heart rate decreased by 13.6% (from 85 to 73 bpm; p < 0.009) with the use of beta-blockers; however, aortic root diameter increased by 1.4 mm/year (p < 0.02). One child could not be given beta-blockers due to bronchial asthma, and no significant side effects were observed in the remaining children, including one who also had bronchial asthma.
Conclusion:
The children remained asymptomatic throughout the study, the use of beta-blockers led to a significant decrease in heart rate, and no significant adverse effects were observed. Contrary to the literature, incidence of annuloaortic ectasia was high among the study population, greater than that of mitral valve prolapse, even during beta-blocker therapy.
Related Concept Videos
Mitral Stenosis II: Clinical features and Diagnostic Tests
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome III: Diagnostic Studies
